You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Populating MPS database with data from multi-organ, human-on-a-chip microphysiological systems
SBC: HESPEROS, INC Topic: 100Project Summary/Abstract: As stated in the Notice of Special Interest announcement, there is a need to populate the recently established MPS database with existing data generated by organ-on-a-chip systems. Having a centralized, public database with data from all available MPS systems will accelerate development and acceptance of the technology ultimately bringing better therapies to patients fast ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty
SBC: Longeveron LLC Topic: NIAAging Frailty is a biologically driven geriatric syndrome of multisystem physiological decline that is distinct from normal aging and disproportionately increases vulnerability to adverse clinical outcomes. Frailty has an overall prevalence of 10% of those 65 years and older, and there is growing awareness in the geriatric community to diagnose and treat this condition, as it is not an inevitable ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Increasing size of Phase 2b clinical trial to 60 patients
SBC: PAIN THERAPEUTICS, INC. Topic: NIAProject Summary/Abstract PTI-125 is a novel small molecule Alzheimer’s disease (AD) therapeutic candidate with a novel target and mechanism of action. PTI-125 binds and reverses an altered conformation of the scaffolding protein filamin A (FLNA) to prevent Aβ42’s tight binding to and toxic signaling via the α7-nicotinic acetylcholine receptor (α7nAChR) as well as Aβ42’s aberrant activati ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Functional integrated human-on-a-chip systems for Alzheimer's research
SBC: HESPEROS, INC Topic: NIAProject SummaryThe goal of this proposal, at the end of the Phase II effort, is to have a service available to academia and industry to screen drugs for Alzheimer’s to predict patient outcomes and determine how potential therapeutics are delivered to the CNS. There are currently few companies able to offer multi-organ evaluation with a recirculating medium utilizing functional readouts, and none ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Development and Preclinical Testing of the TORVAD Ventricular Assist System in Preparation for First in Human Implantation
SBC: WINDMILL CARDIOVASCULAR Topic: NHLBIDESCRIPTIONprovided by applicantThe TORVAD tmis a unique ventricular assist system that delivers low shearsynchronouspulsatile flowBlood shear due to pumping is minimized by the relatively low speed of pistons supported by hydrodynamic bearings designed to maintain a fixed gap between the piston and torus wallsThe TORVAD synchronizes with the heart to preserve aortic valve flow and maintains autor ...
SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Development and Preclinical Testing of the TORVAD Ventricular Assist System in Preparation for First in Human Implantation
SBC: WINDMILL CARDIOVASCULAR Topic: NHLBIDESCRIPTIONprovided by applicantThe TORVAD tmis a unique ventricular assist system that delivers low shearsynchronouspulsatile flowBlood shear due to pumping is minimized by the relatively low speed of pistons supported by hydrodynamic bearings designed to maintain a fixed gap between the piston and torus wallsThe TORVAD synchronizes with the heart to preserve aortic valve flow and maintains autor ...
SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
TP508: A New Drug for Mitigating Lethals Effects of Radiation Exposure
SBC: Chrysalis BioTherapeutics, Inc. Topic: NIAIDDESCRIPTIONprovided by applicantWith increasing risk of a nuclear accident or detonationthere is a critical need to develop effective medicinal countermeasures that can be delivered to victims after an incident to increase survival and prevent long term effects in those that surviveMajor causes of death following a nuclear incident include acute radiation syndromesARSthat destroy hematopoietic ste ...
SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Advanced development of a novel nanoparticle conjugate vaccine for Salmonella Paratyphi A
SBC: KJ BIOSCIENCES LLC Topic: NIAIDSalmonella Paratyphi ASParatyphi Ais a major cause of life threatening enteric feverThere is no vaccine available against this pathogenIn the SBIR phase I studieswe have successfully demonstrated the technical feasibility of a novel nanoparticle conjugate vaccine candidate for SParatyphi AIt is based on O polysaccharideOPSantigen conjugated to a novel and highly advantageous nanoparticle protein c ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Rapid Identification of Pathogenic Bacteria in Blood causing Sepsis
SBC: ISENSE, LLC Topic: NIAIDSepsis is the leading cause of deaths in US hospitals contributing to or causingof all UShospital deaths and is the most expensive condition treated in US hospitalscosting more than $billion annuallyMore thanmillion blood culture bottles are produced annuallywith a marketsize greater than $B in the US and EU aloneThe two year phase II period spanned Februaryto FebruaryRAIThedevelopmentsfunded in p ...
SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of OCF001 for Treatment of Yeast Infections
SBC: Sano Chemicals, Inc. Topic: NIAIDProject Summary Occidiofungins (A-D) are cyclic nonribosomally synthesized antifungal peptides with submicromolar fungicidal activity against a broad spectrum of fungi. Optimization of the production and isolation of occidiofungins from liquid cultures has been performed. The production and isolation of predominantly one analog, called occidiofungin B (OCF001), supports its commercial development ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health